GEN News Highlights: Aug 20, 2010

California Institute for Regenerative Medicine Bankrolls 12 Grants with $243M

California Institute for Regenerative Medicine Bankrolls 12 Grants with $243M

Teams beginning clinical studies or completing early-stage trials within four years will be supported. [© Elena Pankova - Fotolia.com]

(Page 1 of 1)

    The California Institute for Regenerative Medicine (CIRM) approved the concept for up to $243 million in funding to move stem cell-based therapies into clinical trials. The CIRM Disease Team Awards II will support up to 12 awards worth up to $20 million each.

    The funding round represents the second in a recurring round of funding intended to support multidisciplinary teams of researchers working toward filing a request to begin clinical trials or completing Phase I or II studies within four years. By funding teams rather than individual researchers, CIRM acknowledges the varied expertise required for translational and clinical research. The agency will actively encourage industry participation.

    Applications will take place in two parts. A lead investigator must first apply for a Disease Team Planning Award of up to $110,000, which will fund approximately 35 grants to assemble teams, plan, and prepare their more elaborate Disease Team Award application. Only those teams that receive a planning award can submit an application for the full Disease Team Award. Recipients of the first round of Disease Team Awards will be able to request approval to expand their projects to include post-IND activities including clinical trials using unspent funds from the original grant.

    Separately, CIRM’s board voted to fund an independent assessment by the Institute of Medicine of the National Academies of Science to promote public accountability and obtain an independent evaluation of the performance and standards of the stem cell agency. This study will be paid for out of donor funds contributed to the agency specifically to pay for studies and workshops. The report would have a goal of completion within 22 to 26 months, with recommendations for short-, medium-, and long-term actions to improve the performance of the agency.

    The board also voted to support Assembly Bill 52, California Umbilical Cord Blood Collection Program, which requests that the University of California establish and administer the Umbilical Cord Blood Collection Program.


Related content

GEN News Highlights

Insight & Intelligence™

GEN Articles

BLOG biotech

GEN Podcasts

Video Channel

New Products

Best of the Web

GEN Polls

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe

e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
  Confirm Email
  First Name
  Last Name
  Organization
  E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

FDA Performance

How much progress do you think FDA has made in reviewing drugs and bringing them to market faster?

Suggest a Poll